SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXT_B_MTXB2000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1g6v	ANTIBODY HEAVY CHAIN (Camelus dromedarius)	PF07686 (V-set)	6	VAL K 802 LEU K 804 ALA K 824 MET K 834 VAL K 877 TYR K 915	None	0.69A	3qxtB-1g6vK: 20.8	3qxtB-1g6vK: 70.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	6	LEU A 4 ALA A 24 ARG A 77 VAL A 84 ALA A 103 TYR A 118	None None None None None CGN A 1 ( 4.0A)	0.73A	3qxtB-1i3uA: 20.9	3qxtB-1i3uA: 60.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 LEU B 4 ALA B 24 MET B 34 ALA B 94 TYR B 102	None	0.91A	3qxtB-1kxtB: 19.9	3qxtB-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1sjx	IMMUNOGLOBULIN VH DOMAIN (Lama glama)	PF07686 (V-set)	6	VAL A 802 LEU A 804 MET A 834 VAL A 878 ALA A 897 TYR A 908	None None MPD A8001 ( 3.5A) None None None	0.87A	3qxtB-1sjxA: 21.0	3qxtB-1sjxA: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	6	LEU H 4 ALA H 24 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.68A	3qxtB-1t66H: 19.7	3qxtB-1t66H: 31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	6	VAL H 2 LEU H 4 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.69A	3qxtB-1t66H: 19.7	3qxtB-1t66H: 31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	6	LEU A 4 ALA A 24 MET A 34 VAL A 80 ALA A 99 TYR A 115	None	0.55A	3qxtB-2x6mA: 21.5	3qxtB-2x6mA: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	6	LEU A 4 MET A 34 ARG A 73 VAL A 80 ALA A 99 TYR A 115	None	0.91A	3qxtB-2x6mA: 21.5	3qxtB-2x6mA: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	6	LEU A 4 SER A 29 MET A 34 VAL A 78 ALA A 94 TYR A 102	None SO4 A1114 (-2.7A) None None None None	0.78A	3qxtB-2xa3A: 21.2	3qxtB-2xa3A: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3eak	NBBCII10-FGLA (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 2 LEU A 4 ALA A 24 ARG A 75 ALA A 101 TYR A 117	None	0.76A	3qxtB-3eakA: 21.9	3qxtB-3eakA: 67.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	8	VAL B 2 LEU B 4 ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94 TYR B 102	None	0.71A	3qxtB-3g9aB: 20.2	3qxtB-3g9aB: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3if1	IMMUNOGLOBULIN HEAVY CHAIN (IGG2A) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	6	VAL B 2 LEU B 4 ALA B 24 MET B 34 ARG B 71 TYR B 102	None	0.67A	3qxtB-3if1B: 20.1	3qxtB-3if1B: 32.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	6	LEU A 4 ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 111	None	0.69A	3qxtB-3k7uA: 22.5	3qxtB-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	6	LEU A 4 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 111	None	0.33A	3qxtB-3k7uA: 22.5	3qxtB-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	8	VAL A 4 LEU A 6 ALA A 26 SER A 30 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	0.86A	3qxtB-3qxuA: 24.9	3qxtB-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	9	VAL A 4 LEU A 6 ALA A 26 SER A 31 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	0.78A	3qxtB-3qxuA: 24.9	3qxtB-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	6	VAL A 4 LEU A 6 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.57A	3qxtB-3qycA: 20.2	3qxtB-3qycA: 62.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r0m	LLAMA VHH A12 (Lama glama)	PF07686 (V-set)	6	LEU A 4 ALA A 24 SER A 29 MET A 34 VAL A 78 ALA A 94	None None SO4 A 131 (-2.7A) None None None	0.83A	3qxtB-3r0mA: 21.3	3qxtB-3r0mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	LEU A 6 ALA A 26 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.52A	3qxtB-3stbA: 22.3	3qxtB-3stbA: 71.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	VAL A 4 LEU A 6 ALA A 26 MET A 36 ARG A 73 VAL A 80	None	0.78A	3qxtB-3stbA: 22.3	3qxtB-3stbA: 71.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tpk	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1 (Camelidae)	PF07686 (V-set)	6	VAL A 2 LEU A 4 ALA A 24 VAL A 79 ALA A 98 TYR A 110	None BEN A 133 (-4.7A) BEN A 133 (-3.6A) BEN A 133 (-4.6A) BEN A 133 ( 4.2A) None	0.78A	3qxtB-3tpkA: 21.0	3qxtB-3tpkA: 64.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	7	LEU A 4 ALA A 24 SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98	None	1.25A	3qxtB-4dkaA: 22.4	3qxtB-4dkaA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	8	VAL A 2 LEU A 4 ALA A 24 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 116	None	0.72A	3qxtB-4dkaA: 22.4	3qxtB-4dkaA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	7	LEU B 4 ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 97 TYR B 106	None	0.63A	3qxtB-4eigB: 20.5	3qxtB-4eigB: 67.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ej1	NB113 CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	LEU C 4 ALA C 24 MET C 34 ARG C 72 VAL C 79 ALA C 98	None	0.59A	3qxtB-4ej1C: 21.9	3qxtB-4ej1C: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f58	HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3 (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 LEU H 4 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	0.85A	3qxtB-4f58H: 20.5	3qxtB-4f58H: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	6	LEU D 4 MET D 34 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.59A	3qxtB-4fhbD: 21.5	3qxtB-4fhbD: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	6	LEU B 5 MET B 36 ARG B 74 VAL B 81 ALA B 100 TYR B 115	None None None None None PCA B 2 ( 3.9A)	0.34A	3qxtB-4gftB: 22.5	3qxtB-4gftB: 66.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	7	LEU E 4 ALA E 24 MET E 34 ARG E 72 VAL E 79 ALA E 98 TYR E 112	None	0.54A	3qxtB-4hemE: 23.4	3qxtB-4hemE: 74.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hlz	FAB C179 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	6	VAL G 2 LEU G 4 MET G 34 ARG G 71 VAL G 78 TYR G 102	None	0.67A	3qxtB-4hlzG: 19.5	3qxtB-4hlzG: 53.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	7	LEU B 4 ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.58A	3qxtB-4krmB: 23.6	3qxtB-4krmB: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	7	LEU B 4 SER B 29 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.91A	3qxtB-4krmB: 23.6	3qxtB-4krmB: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lde	CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	VAL B 2 LEU B 4 MET B 34 ARG B 71 VAL B 78 TYR B 109	None	0.80A	3qxtB-4ldeB: 19.6	3qxtB-4ldeB: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	LEU B 4 ALA B 24 SER B 28 MET B 34 ARG B 72 VAL B 79	None	0.76A	3qxtB-4lhqB: 22.0	3qxtB-4lhqB: 64.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4mqt	NANOBODY 9-8 (Lama glama)	PF07686 (V-set)	6	VAL B 2 LEU B 4 ALA B 24 VAL B 82 ALA B 101 TYR B 110	None	0.69A	3qxtB-4mqtB: 19.1	3qxtB-4mqtB: 63.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4n1h	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N (Lama glama)	PF07686 (V-set)	6	LEU B 4 ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.68A	3qxtB-4n1hB: 21.6	3qxtB-4n1hB: 70.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	8	VAL C 9 LEU C 11 ALA C 31 MET C 41 ARG C 79 VAL C 86 ALA C 105 TYR C 119	None	0.87A	3qxtB-4nc1C: 22.3	3qxtB-4nc1C: 70.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	6	LEU B 4 ALA B 24 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.61A	3qxtB-4nc2B: 23.7	3qxtB-4nc2B: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	6	VAL B 2 LEU B 4 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.55A	3qxtB-4nc2B: 23.7	3qxtB-4nc2B: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	7	VAL G 2 LEU G 4 MET G 34 ARG G 71 VAL G 78 ALA G 97 TYR G 111	None	0.63A	3qxtB-4p2cG: 19.4	3qxtB-4p2cG: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	6	LEU A 4 ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None	0.64A	3qxtB-4qlrA: 22.9	3qxtB-4qlrA: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	6	VAL A 2 LEU A 4 ALA A 24 ARG A 72 ALA A 98 TYR A 113	None	0.87A	3qxtB-4qlrA: 22.9	3qxtB-4qlrA: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	7	LEU A 5 ALA A 25 MET A 35 ARG A 73 VAL A 80 ALA A 99 TYR A 113	None	0.50A	3qxtB-4qo1A: 21.2	3qxtB-4qo1A: 63.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	6	LEU a 5 ALA a 25 ARG a 73 VAL a 80 ALA a 99 TYR a 117	None	0.65A	3qxtB-4tvsa: 22.8	3qxtB-4tvsa: 73.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	0.86A	3qxtB-4w6yB: 21.5	3qxtB-4w6yB: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	7	VAL D 802 LEU D 804 ALA D 824 MET D 834 ARG D 872 ALA D 898 TYR D 910	None	0.61A	3qxtB-4weuD: 22.5	3qxtB-4weuD: 72.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4x8j	12F4 FAB HEAVY CHAIN (Mus musculus)	no annotation	6	VAL H 2 LEU H 4 MET H 34 ARG H 74 VAL H 81 TYR H 104	None None None None None 2PE H 302 ( 4.6A)	0.65A	3qxtB-4x8jH: 15.8	3qxtB-4x8jH: 34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	7	VAL C 2 LEU C 4 ALA C 24 MET C 34 VAL C 78 ALA C 97 TYR C 107	None	0.88A	3qxtB-4xt1C: 19.5	3qxtB-4xt1C: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydk	HEAVY CHAIN OF ANTIBODY C38-VRC16.01 (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 LEU H 4 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	0.89A	3qxtB-4ydkH: 20.4	3qxtB-4ydkH: 35.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	7	VAL H 2 LEU H 4 ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.74A	3qxtB-5a2kH: 20.2	3qxtB-5a2kH: 29.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	6	LEU H 4 ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.63A	3qxtB-5aumH: 20.1	3qxtB-5aumH: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	6	VAL H 2 LEU H 4 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.60A	3qxtB-5aumH: 20.1	3qxtB-5aumH: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 LEU A 6 ALA A 26 ARG A 73 VAL A 80 ALA A 99	None	0.87A	3qxtB-5e7fA: 19.0	3qxtB-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 LEU A 6 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.66A	3qxtB-5e7fA: 19.0	3qxtB-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	8	VAL A 2 LEU A 4 ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.79A	3qxtB-5fwoA: 21.9	3qxtB-5fwoA: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	1.03A	3qxtB-5gxbB: 21.1	3qxtB-5gxbB: 69.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hm1	LAMA VHH ANTIBODY 2E7 (Lama glama)	PF07686 (V-set)	6	VAL A 2 LEU A 4 ALA A 24 VAL A 78 ALA A 94 TYR A 102	None	0.74A	3qxtB-5hm1A: 18.7	3qxtB-5hm1A: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 ARG B 70 VAL B 77 ALA B 96 TYR B 108	None	0.79A	3qxtB-5hvfB: 18.7	3qxtB-5hvfB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 MET B 34 VAL B 77 ALA B 96 TYR B 108	None	0.94A	3qxtB-5hvfB: 18.7	3qxtB-5hvfB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	7	LEU B 3 ALA B 23 MET B 33 ARG B 71 VAL B 78 ALA B 97 TYR B 113	None	0.64A	3qxtB-5imlB: 24.0	3qxtB-5imlB: 76.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	8	VAL C 3 LEU C 5 ALA C 25 MET C 35 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.81A	3qxtB-5j1sC: 19.9	3qxtB-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 ARG B 76 VAL B 83 ALA B 102 TYR B 117	None	0.81A	3qxtB-5j56B: 21.3	3qxtB-5j56B: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	6	VAL D 2 LEU D 4 MET D 34 ARG D 71 VAL D 78 ALA D 97	None	0.84A	3qxtB-5jqhD: 19.5	3qxtB-5jqhD: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 LEU B 4 ALA B 24 ARG B 72 VAL B 79 ALA B 98 TYR B 122	None	0.61A	3qxtB-5lhqB: 22.0	3qxtB-5lhqB: 65.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhr	CAMELID-DERIVED ANTIBODY FRAGMENT NB22 (Vicugna pacos)	PF07686 (V-set)	6	LEU B 4 ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.83A	3qxtB-5lhrB: 20.0	3qxtB-5lhrB: 76.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	7	LEU A 4 ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.98A	3qxtB-5lmjA: 20.5	3qxtB-5lmjA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	7	LEU C 7 ALA C 27 MET C 37 ARG C 75 VAL C 82 ALA C 101 TYR C 117	None None None None None None ACT C 202 (-4.4A)	0.48A	3qxtB-5lwfC: 21.7	3qxtB-5lwfC: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5m13	SYNTHETIC NANOBODY L2_C06 (A-MBP#2) (synthetic construct)	no annotation	6	VAL B 2 LEU B 4 ALA B 24 VAL B 79 ALA B 98 TYR B 114	None	0.75A	3qxtB-5m13B: 22.5	3qxtB-5m13B: 64.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 LEU C 4 MET C 34 ARG C 72 ALA C 98 TYR C 113	None	0.57A	3qxtB-5o02C: 21.6	3qxtB-5o02C: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o03	NANOBODY (VHH) NANO-32 (Norwalk virus)	PF07686 (V-set)	6	LEU C 4 ALA C 24 ARG C 72 VAL C 79 ALA C 98 TYR C 124	None	0.85A	3qxtB-5o03C: 20.9	3qxtB-5o03C: 64.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o04	NANOBODY (VHH) NANO-26 (Vicugna pacos)	PF07686 (V-set)	6	VAL E 2 LEU E 4 ALA E 24 ARG E 71 VAL E 78 TYR E 104	None	0.87A	3qxtB-5o04E: 18.9	3qxtB-5o04E: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o05	NANOBODY (VHH) NANO-42 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 LEU C 4 ALA C 24 SER C 29 VAL C 78 TYR C 109	None	0.81A	3qxtB-5o05C: 17.1	3qxtB-5o05C: 66.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	6	LEU L 4 ALA L 24 MET L 34 VAL L 79 ALA L 98 TYR L 114	None	0.79A	3qxtB-5o8fL: 22.0	3qxtB-5o8fL: 69.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	6	LEU L 4 MET L 34 ARG L 72 VAL L 79 ALA L 98 TYR L 114	None	0.61A	3qxtB-5o8fL: 22.0	3qxtB-5o8fL: 69.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ocl	ANTI-VGLUT NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL B 4 LEU B 6 ALA B 26 VAL B 81 ALA B 100 TYR B 115	None	0.74A	3qxtB-5oclB: 20.1	3qxtB-5oclB: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td8	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL E 3 LEU E 5 ALA E 25 VAL E 80 ALA E 99 TYR E 117	None	0.78A	3qxtB-5td8E: 18.7	3qxtB-5td8E: 68.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	LEU p 4 ALA p 24 MET p 34 ARG p 72 ALA p 98 TYR p 114	None	0.76A	3qxtB-5uk4p: 21.8	3qxtB-5uk4p: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	7	VAL p 2 LEU p 4 MET p 34 ARG p 72 VAL p 79 ALA p 98 TYR p 114	None	0.72A	3qxtB-5uk4p: 21.8	3qxtB-5uk4p: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	LEU d 4 ALA d 24 ARG d 72 VAL d 79 ALA d 98 TYR d 113	None	0.66A	3qxtB-5ukbd: 22.6	3qxtB-5ukbd: 72.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	LEU d 4 ARG d 30 ARG d 72 VAL d 79 ALA d 98 TYR d 113	None	0.78A	3qxtB-5ukbd: 22.6	3qxtB-5ukbd: 72.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	VAL d 2 LEU d 4 ALA d 24 VAL d 79 ALA d 98 TYR d 113	None	0.89A	3qxtB-5ukbd: 22.6	3qxtB-5ukbd: 72.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vaq	NB914 (Lama glama)	no annotation	6	LEU B 4 ALA B 24 SER B 30 ARG B 72 VAL B 79 ALA B 98	None	0.79A	3qxtB-5vaqB: 22.9	3qxtB-5vaqB: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vgj	VRC38.01 FAB HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 LEU H 4 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	0.56A	3qxtB-5vgjH: 19.4	3qxtB-5vgjH: 37.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	7	VAL B 2 LEU B 4 ALA B 24 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.99A	3qxtB-5vxjB: 19.6	3qxtB-5vxjB: 63.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	7	VAL B 2 LEU B 4 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.69A	3qxtB-5vxjB: 19.6	3qxtB-5vxjB: 63.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	7	LEU B 4 ALA B 24 MET B 34 ARG B 73 VAL B 80 ALA B 99 TYR B 106	None	0.59A	3qxtB-5vxlB: 20.7	3qxtB-5vxlB: 64.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	7	VAL A1002 LEU A1004 ALA A1024 MET A1034 VAL A1078 ALA A1097 TYR A1107	None	0.94A	3qxtB-5wb1A: 18.4	3qxtB-5wb1A: 14.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wb2	NANOBODY B1 (synthetic construct)	no annotation	6	LEU D 4 ALA D 24 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.82A	3qxtB-5wb2D: 19.0	3qxtB-5wb2D: 69.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	6	LEU A 23 ALA A 43 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.69A	3qxtB-5x0tA: 20.1	3qxtB-5x0tA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	6	VAL A 21 LEU A 23 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.72A	3qxtB-5x0tA: 20.1	3qxtB-5x0tA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5xjm	FABH (Mus musculus)	no annotation	6	VAL H 2 LEU H 4 ALA H 24 MET H 34 ARG H 72 TYR H 109	None	0.86A	3qxtB-5xjmH: 21.4	3qxtB-5xjmH: 59.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6d11	1450 ANTIBODY, HEAVY CHAIN (Homo sapiens)	no annotation	6	VAL A 2 LEU A 4 ALA A 24 MET A 34 ARG A 71 VAL A 78	None	0.82A	3qxtB-6d11A: 20.5	3qxtB-6d11A: 53.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	7	LEU A 4 SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 107	None	1.17A	3qxtB-6dbeA: 20.8	3qxtB-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	7	VAL A 2 LEU A 4 ALA A 24 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.66A	3qxtB-6dbeA: 20.8	3qxtB-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	7	VAL A 2 LEU A 4 SER A 30 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.93A	3qxtB-6dbeA: 20.8	3qxtB-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	6	LEU C 4 ALA C 24 MET C 34 ARG C 72 VAL C 79 ALA C 98	None	0.59A	3qxtB-6ehgC: 22.5	3qxtB-6ehgC: 74.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	6	LEU C 4 MET C 34 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.61A	3qxtB-6ehgC: 22.5	3qxtB-6ehgC: 74.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	6	VAL C 2 LEU C 4 ALA C 24 MET C 34 ARG C 72 VAL C 79	None	0.81A	3qxtB-6ehgC: 22.5	3qxtB-6ehgC: 74.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	6	VAL C 2 LEU C 4 MET C 34 ARG C 72 VAL C 79 TYR C 112	None	0.86A	3qxtB-6ehgC: 22.5	3qxtB-6ehgC: 74.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	7	VAL A 2 LEU A 4 ALA A 24 MET A 34 ARG A 71 ALA A 94 TYR A 102	None	0.68A	3qxtB-6gzpA: 22.0	3qxtB-6gzpA: undetectable

[["3QXT_B_MTXB2000_1","1g6v","Camelus dromedarius","ANTIBODY HEAVY CHAIN","PF07686(V-set)",6,"VAL K 802;LEU K 804;ALA K 824;MET K 834;VAL K 877;TYR K 915","None","0.69A","3qxtB-1g6vK:20.8","3qxtB-1g6vK:70.31"],["3QXT_B_MTXB2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",6,"LEU A   4;ALA A  24;ARG A  77;VAL A  84;ALA A 103;TYR A 118","None;None;None;None;None;CGN A   1 ( 4.0A)","0.73A","3qxtB-1i3uA:20.9","3qxtB-1i3uA:60.58"],["3QXT_B_MTXB2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",6,"VAL B   2;LEU B   4;ALA B  24;MET B  34;ALA B  94;TYR B 102","None","0.91A","3qxtB-1kxtB:19.9","3qxtB-1kxtB:68.75"],["3QXT_B_MTXB2000_1","1sjx","Lama glama","IMMUNOGLOBULIN VH DOMAIN","PF07686(V-set)",6,"VAL A 802;LEU A 804;MET A 834;VAL A 878;ALA A 897;TYR A 908","None;None;MPD A8001 ( 3.5A);None;None;None","0.87A","3qxtB-1sjxA:21.0","3qxtB-1sjxA:69.60"],["3QXT_B_MTXB2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",6,"LEU H   4;ALA H  24;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.68A","3qxtB-1t66H:19.7","3qxtB-1t66H:31.90"],["3QXT_B_MTXB2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",6,"VAL H   2;LEU H   4;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.69A","3qxtB-1t66H:19.7","3qxtB-1t66H:31.90"],["3QXT_B_MTXB2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",6,"LEU A   4;ALA A  24;MET A  34;VAL A  80;ALA A  99;TYR A 115","None","0.55A","3qxtB-2x6mA:21.5","3qxtB-2x6mA:69.77"],["3QXT_B_MTXB2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",6,"LEU A   4;MET A  34;ARG A  73;VAL A  80;ALA A  99;TYR A 115","None","0.91A","3qxtB-2x6mA:21.5","3qxtB-2x6mA:69.77"],["3QXT_B_MTXB2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",6,"LEU A   4;SER A  29;MET A  34;VAL A  78;ALA A  94;TYR A 102","None;SO4 A1114 (-2.7A);None;None;None;None","0.78A","3qxtB-2xa3A:21.2","3qxtB-2xa3A:69.77"],["3QXT_B_MTXB2000_1","3eak","Camelus dromedarius","NBBCII10-FGLA","PF07686(V-set)",6,"VAL A   2;LEU A   4;ALA A  24;ARG A  75;ALA A 101;TYR A 117","None","0.76A","3qxtB-3eakA:21.9","3qxtB-3eakA:67.19"],["3QXT_B_MTXB2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",8,"VAL B   2;LEU B   4;ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94;TYR B 102","None","0.71A","3qxtB-3g9aB:20.2","3qxtB-3g9aB:66.42"],["3QXT_B_MTXB2000_1","3if1","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN (IGG2A)","PF07654(C1-set);PF07686(V-set)",6,"VAL B   2;LEU B   4;ALA B  24;MET B  34;ARG B  71;TYR B 102","None","0.67A","3qxtB-3if1B:20.1","3qxtB-3if1B:32.69"],["3QXT_B_MTXB2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",6,"LEU A   4;ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 111","None","0.69A","3qxtB-3k7uA:22.5","3qxtB-3k7uA:73.81"],["3QXT_B_MTXB2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",6,"LEU A   4;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 111","None","0.33A","3qxtB-3k7uA:22.5","3qxtB-3k7uA:73.81"],["3QXT_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",8,"VAL A   4;LEU A   6;ALA A  26;SER A  30;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","0.86A","3qxtB-3qxuA:24.9","3qxtB-3qxuA:100.00"],["3QXT_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",9,"VAL A   4;LEU A   6;ALA A  26;SER A  31;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","0.78A","3qxtB-3qxuA:24.9","3qxtB-3qxuA:100.00"],["3QXT_B_MTXB2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",6,"VAL A   4;LEU A   6;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.57A","3qxtB-3qycA:20.2","3qxtB-3qycA:62.99"],["3QXT_B_MTXB2000_1","3r0m","Lama glama","LLAMA VHH A12","PF07686(V-set)",6,"LEU A   4;ALA A  24;SER A  29;MET A  34;VAL A  78;ALA A  94","None;None;SO4 A 131 (-2.7A);None;None;None","0.83A","3qxtB-3r0mA:21.3","3qxtB-3r0mA:70.54"],["3QXT_B_MTXB2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"LEU A   6;ALA A  26;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.52A","3qxtB-3stbA:22.3","3qxtB-3stbA:71.54"],["3QXT_B_MTXB2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"VAL A   4;LEU A   6;ALA A  26;MET A  36;ARG A  73;VAL A  80","None","0.78A","3qxtB-3stbA:22.3","3qxtB-3stbA:71.54"],["3QXT_B_MTXB2000_1","3tpk","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1","PF07686(V-set)",6,"VAL A   2;LEU A   4;ALA A  24;VAL A  79;ALA A  98;TYR A 110","None;BEN A 133 (-4.7A);BEN A 133 (-3.6A);BEN A 133 (-4.6A);BEN A 133 ( 4.2A);None","0.78A","3qxtB-3tpkA:21.0","3qxtB-3tpkA:64.84"],["3QXT_B_MTXB2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",7,"LEU A   4;ALA A  24;SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98","None","1.25A","3qxtB-4dkaA:22.4","3qxtB-4dkaA:74.02"],["3QXT_B_MTXB2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",8,"VAL A   2;LEU A   4;ALA A  24;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 116","None","0.72A","3qxtB-4dkaA:22.4","3qxtB-4dkaA:74.02"],["3QXT_B_MTXB2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",7,"LEU B   4;ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  97;TYR B 106","None","0.63A","3qxtB-4eigB:20.5","3qxtB-4eigB:67.74"],["3QXT_B_MTXB2000_1","4ej1","Lama glama","NB113 CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",6,"LEU C   4;ALA C  24;MET C  34;ARG C  72;VAL C  79;ALA C  98","None","0.59A","3qxtB-4ej1C:21.9","3qxtB-4ej1C:75.00"],["3QXT_B_MTXB2000_1","4f58","Homo sapiens","HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;LEU H   4;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","0.85A","3qxtB-4f58H:20.5","3qxtB-4f58H:61.42"],["3QXT_B_MTXB2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",6,"LEU D   4;MET D  34;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.59A","3qxtB-4fhbD:21.5","3qxtB-4fhbD:72.09"],["3QXT_B_MTXB2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",6,"LEU B   5;MET B  36;ARG B  74;VAL B  81;ALA B 100;TYR B 115","None;None;None;None;None;PCA B   2 ( 3.9A)","0.34A","3qxtB-4gftB:22.5","3qxtB-4gftB:66.14"],["3QXT_B_MTXB2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",7,"LEU E   4;ALA E  24;MET E  34;ARG E  72;VAL E  79;ALA E  98;TYR E 112","None","0.54A","3qxtB-4hemE:23.4","3qxtB-4hemE:74.19"],["3QXT_B_MTXB2000_1","4hlz","Mus musculus","FAB C179 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",6,"VAL G   2;LEU G   4;MET G  34;ARG G  71;VAL G  78;TYR G 102","None","0.67A","3qxtB-4hlzG:19.5","3qxtB-4hlzG:53.12"],["3QXT_B_MTXB2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",7,"LEU B   4;ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.58A","3qxtB-4krmB:23.6","3qxtB-4krmB:70.97"],["3QXT_B_MTXB2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",7,"LEU B   4;SER B  29;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.91A","3qxtB-4krmB:23.6","3qxtB-4krmB:70.97"],["3QXT_B_MTXB2000_1","4lde","Lama glama","CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",6,"VAL B   2;LEU B   4;MET B  34;ARG B  71;VAL B  78;TYR B 109","None","0.80A","3qxtB-4ldeB:19.6","3qxtB-4ldeB:68.55"],["3QXT_B_MTXB2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",6,"LEU B   4;ALA B  24;SER B  28;MET B  34;ARG B  72;VAL B  79","None","0.76A","3qxtB-4lhqB:22.0","3qxtB-4lhqB:64.06"],["3QXT_B_MTXB2000_1","4mqt","Lama glama","NANOBODY 9-8","PF07686(V-set)",6,"VAL B   2;LEU B   4;ALA B  24;VAL B  82;ALA B 101;TYR B 110","None","0.69A","3qxtB-4mqtB:19.1","3qxtB-4mqtB:63.36"],["3QXT_B_MTXB2000_1","4n1h","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N","PF07686(V-set)",6,"LEU B   4;ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.68A","3qxtB-4n1hB:21.6","3qxtB-4n1hB:70.08"],["3QXT_B_MTXB2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",8,"VAL C   9;LEU C  11;ALA C  31;MET C  41;ARG C  79;VAL C  86;ALA C 105;TYR C 119","None","0.87A","3qxtB-4nc1C:22.3","3qxtB-4nc1C:70.99"],["3QXT_B_MTXB2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",6,"LEU B   4;ALA B  24;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.61A","3qxtB-4nc2B:23.7","3qxtB-4nc2B:71.77"],["3QXT_B_MTXB2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",6,"VAL B   2;LEU B   4;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.55A","3qxtB-4nc2B:23.7","3qxtB-4nc2B:71.77"],["3QXT_B_MTXB2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",7,"VAL G   2;LEU G   4;MET G  34;ARG G  71;VAL G  78;ALA G  97;TYR G 111","None","0.63A","3qxtB-4p2cG:19.4","3qxtB-4p2cG:71.77"],["3QXT_B_MTXB2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",6,"LEU A   4;ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None","0.64A","3qxtB-4qlrA:22.9","3qxtB-4qlrA:70.63"],["3QXT_B_MTXB2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",6,"VAL A   2;LEU A   4;ALA A  24;ARG A  72;ALA A  98;TYR A 113","None","0.87A","3qxtB-4qlrA:22.9","3qxtB-4qlrA:70.63"],["3QXT_B_MTXB2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",7,"LEU A   5;ALA A  25;MET A  35;ARG A  73;VAL A  80;ALA A  99;TYR A 113","None","0.50A","3qxtB-4qo1A:21.2","3qxtB-4qo1A:63.49"],["3QXT_B_MTXB2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",6,"LEU a   5;ALA a  25;ARG a  73;VAL a  80;ALA a  99;TYR a 117","None","0.65A","3qxtB-4tvsa:22.8","3qxtB-4tvsa:73.64"],["3QXT_B_MTXB2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","0.86A","3qxtB-4w6yB:21.5","3qxtB-4w6yB:70.23"],["3QXT_B_MTXB2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",7,"VAL D 802;LEU D 804;ALA D 824;MET D 834;ARG D 872;ALA D 898;TYR D 910","None","0.61A","3qxtB-4weuD:22.5","3qxtB-4weuD:72.80"],["3QXT_B_MTXB2000_1","4x8j","Mus musculus","12F4 FAB HEAVY CHAIN","no annotation",6,"VAL H   2;LEU H   4;MET H  34;ARG H  74;VAL H  81;TYR H 104","None;None;None;None;None;2PE H 302 ( 4.6A)","0.65A","3qxtB-4x8jH:15.8","3qxtB-4x8jH:34.78"],["3QXT_B_MTXB2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",7,"VAL C   2;LEU C   4;ALA C  24;MET C  34;VAL C  78;ALA C  97;TYR C 107","None","0.88A","3qxtB-4xt1C:19.5","3qxtB-4xt1C:68.75"],["3QXT_B_MTXB2000_1","4ydk","Homo sapiens","HEAVY CHAIN OF ANTIBODY C38-VRC16.01","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;LEU H   4;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","0.89A","3qxtB-4ydkH:20.4","3qxtB-4ydkH:35.61"],["3QXT_B_MTXB2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",7,"VAL H   2;LEU H   4;ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.74A","3qxtB-5a2kH:20.2","3qxtB-5a2kH:29.44"],["3QXT_B_MTXB2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",6,"LEU H   4;ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.63A","3qxtB-5aumH:20.1","3qxtB-5aumH:38.65"],["3QXT_B_MTXB2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",6,"VAL H   2;LEU H   4;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.60A","3qxtB-5aumH:20.1","3qxtB-5aumH:38.65"],["3QXT_B_MTXB2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;LEU A   6;ALA A  26;ARG A  73;VAL A  80;ALA A  99","None","0.87A","3qxtB-5e7fA:19.0","3qxtB-5e7fA:67.72"],["3QXT_B_MTXB2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;LEU A   6;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.66A","3qxtB-5e7fA:19.0","3qxtB-5e7fA:67.72"],["3QXT_B_MTXB2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",8,"VAL A   2;LEU A   4;ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.79A","3qxtB-5fwoA:21.9","3qxtB-5fwoA:68.42"],["3QXT_B_MTXB2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","1.03A","3qxtB-5gxbB:21.1","3qxtB-5gxbB:69.17"],["3QXT_B_MTXB2000_1","5hm1","Lama glama","LAMA VHH ANTIBODY 2E7","PF07686(V-set)",6,"VAL A   2;LEU A   4;ALA A  24;VAL A  78;ALA A  94;TYR A 102","None","0.74A","3qxtB-5hm1A:18.7","3qxtB-5hm1A:68.80"],["3QXT_B_MTXB2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;ARG B  70;VAL B  77;ALA B  96;TYR B 108","None","0.79A","3qxtB-5hvfB:18.7","3qxtB-5hvfB:70.16"],["3QXT_B_MTXB2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;MET B  34;VAL B  77;ALA B  96;TYR B 108","None","0.94A","3qxtB-5hvfB:18.7","3qxtB-5hvfB:70.16"],["3QXT_B_MTXB2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",7,"LEU B   3;ALA B  23;MET B  33;ARG B  71;VAL B  78;ALA B  97;TYR B 113","None","0.64A","3qxtB-5imlB:24.0","3qxtB-5imlB:76.19"],["3QXT_B_MTXB2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",8,"VAL C   3;LEU C   5;ALA C  25;MET C  35;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.81A","3qxtB-5j1sC:19.9","3qxtB-5j1sC:66.17"],["3QXT_B_MTXB2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;ARG B  76;VAL B  83;ALA B 102;TYR B 117","None","0.81A","3qxtB-5j56B:21.3","3qxtB-5j56B:67.94"],["3QXT_B_MTXB2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",6,"VAL D   2;LEU D   4;MET D  34;ARG D  71;VAL D  78;ALA D  97","None","0.84A","3qxtB-5jqhD:19.5","3qxtB-5jqhD:70.97"],["3QXT_B_MTXB2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",7,"VAL B   2;LEU B   4;ALA B  24;ARG B  72;VAL B  79;ALA B  98;TYR B 122","None","0.61A","3qxtB-5lhqB:22.0","3qxtB-5lhqB:65.41"],["3QXT_B_MTXB2000_1","5lhr","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB22","PF07686(V-set)",6,"LEU B   4;ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.83A","3qxtB-5lhrB:20.0","3qxtB-5lhrB:76.80"],["3QXT_B_MTXB2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",7,"LEU A   4;ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.98A","3qxtB-5lmjA:20.5","3qxtB-5lmjA:74.02"],["3QXT_B_MTXB2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",7,"LEU C   7;ALA C  27;MET C  37;ARG C  75;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;None;None;ACT C 202 (-4.4A)","0.48A","3qxtB-5lwfC:21.7","3qxtB-5lwfC:69.60"],["3QXT_B_MTXB2000_1","5m13","synthetic construct","SYNTHETIC NANOBODY L2_C06 (A-MBP#2)","no annotation",6,"VAL B   2;LEU B   4;ALA B  24;VAL B  79;ALA B  98;TYR B 114","None","0.75A","3qxtB-5m13B:22.5","3qxtB-5m13B:64.39"],["3QXT_B_MTXB2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",6,"VAL C   2;LEU C   4;MET C  34;ARG C  72;ALA C  98;TYR C 113","None","0.57A","3qxtB-5o02C:21.6","3qxtB-5o02C:69.35"],["3QXT_B_MTXB2000_1","5o03","Norwalk virus","NANOBODY (VHH) NANO-32","PF07686(V-set)",6,"LEU C   4;ALA C  24;ARG C  72;VAL C  79;ALA C  98;TYR C 124","None","0.85A","3qxtB-5o03C:20.9","3qxtB-5o03C:64.44"],["3QXT_B_MTXB2000_1","5o04","Vicugna pacos","NANOBODY (VHH) NANO-26","PF07686(V-set)",6,"VAL E   2;LEU E   4;ALA E  24;ARG E  71;VAL E  78;TYR E 104","None","0.87A","3qxtB-5o04E:18.9","3qxtB-5o04E:65.32"],["3QXT_B_MTXB2000_1","5o05","Vicugna pacos","NANOBODY (VHH) NANO-42","PF07686(V-set)",6,"VAL C   2;LEU C   4;ALA C  24;SER C  29;VAL C  78;TYR C 109","None","0.81A","3qxtB-5o05C:17.1","3qxtB-5o05C:66.40"],["3QXT_B_MTXB2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",6,"LEU L   4;ALA L  24;MET L  34;VAL L  79;ALA L  98;TYR L 114","None","0.79A","3qxtB-5o8fL:22.0","3qxtB-5o8fL:69.23"],["3QXT_B_MTXB2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",6,"LEU L   4;MET L  34;ARG L  72;VAL L  79;ALA L  98;TYR L 114","None","0.61A","3qxtB-5o8fL:22.0","3qxtB-5o8fL:69.23"],["3QXT_B_MTXB2000_1","5ocl","Lama glama","ANTI-VGLUT NANOBODY","PF07686(V-set)",6,"VAL B   4;LEU B   6;ALA B  26;VAL B  81;ALA B 100;TYR B 115","None","0.74A","3qxtB-5oclB:20.1","3qxtB-5oclB:73.23"],["3QXT_B_MTXB2000_1","5td8","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL E   3;LEU E   5;ALA E  25;VAL E  80;ALA E  99;TYR E 117","None","0.78A","3qxtB-5td8E:18.7","3qxtB-5td8E:68.22"],["3QXT_B_MTXB2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"LEU p   4;ALA p  24;MET p  34;ARG p  72;ALA p  98;TYR p 114","None","0.76A","3qxtB-5uk4p:21.8","3qxtB-5uk4p:70.63"],["3QXT_B_MTXB2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",7,"VAL p   2;LEU p   4;MET p  34;ARG p  72;VAL p  79;ALA p  98;TYR p 114","None","0.72A","3qxtB-5uk4p:21.8","3qxtB-5uk4p:70.63"],["3QXT_B_MTXB2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"LEU d   4;ALA d  24;ARG d  72;VAL d  79;ALA d  98;TYR d 113","None","0.66A","3qxtB-5ukbd:22.6","3qxtB-5ukbd:72.58"],["3QXT_B_MTXB2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"LEU d   4;ARG d  30;ARG d  72;VAL d  79;ALA d  98;TYR d 113","None","0.78A","3qxtB-5ukbd:22.6","3qxtB-5ukbd:72.58"],["3QXT_B_MTXB2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"VAL d   2;LEU d   4;ALA d  24;VAL d  79;ALA d  98;TYR d 113","None","0.89A","3qxtB-5ukbd:22.6","3qxtB-5ukbd:72.58"],["3QXT_B_MTXB2000_1","5vaq","Lama glama","NB914","no annotation",6,"LEU B   4;ALA B  24;SER B  30;ARG B  72;VAL B  79;ALA B  98","None","0.79A","3qxtB-5vaqB:22.9","3qxtB-5vaqB:76.25"],["3QXT_B_MTXB2000_1","5vgj","Homo sapiens","VRC38.01 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;LEU H   4;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","0.56A","3qxtB-5vgjH:19.4","3qxtB-5vgjH:37.93"],["3QXT_B_MTXB2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",7,"VAL B   2;LEU B   4;ALA B  24;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.99A","3qxtB-5vxjB:19.6","3qxtB-5vxjB:63.85"],["3QXT_B_MTXB2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",7,"VAL B   2;LEU B   4;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.69A","3qxtB-5vxjB:19.6","3qxtB-5vxjB:63.85"],["3QXT_B_MTXB2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",7,"LEU B   4;ALA B  24;MET B  34;ARG B  73;VAL B  80;ALA B  99;TYR B 106","None","0.59A","3qxtB-5vxlB:20.7","3qxtB-5vxlB:64.84"],["3QXT_B_MTXB2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",7,"VAL A1002;LEU A1004;ALA A1024;MET A1034;VAL A1078;ALA A1097;TYR A1107","None","0.94A","3qxtB-5wb1A:18.4","3qxtB-5wb1A:14.29"],["3QXT_B_MTXB2000_1","5wb2","synthetic construct","NANOBODY B1","no annotation",6,"LEU D   4;ALA D  24;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.82A","3qxtB-5wb2D:19.0","3qxtB-5wb2D:69.51"],["3QXT_B_MTXB2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",6,"LEU A  23;ALA A  43;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.69A","3qxtB-5x0tA:20.1","3qxtB-5x0tA:31.40"],["3QXT_B_MTXB2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",6,"VAL A  21;LEU A  23;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.72A","3qxtB-5x0tA:20.1","3qxtB-5x0tA:31.40"],["3QXT_B_MTXB2000_1","5xjm","Mus musculus","FABH","no annotation",6,"VAL H   2;LEU H   4;ALA H  24;MET H  34;ARG H  72;TYR H 109","None","0.86A","3qxtB-5xjmH:21.4","3qxtB-5xjmH:59.52"],["3QXT_B_MTXB2000_1","6d11","Homo sapiens","1450 ANTIBODY, HEAVY CHAIN","no annotation",6,"VAL A   2;LEU A   4;ALA A  24;MET A  34;ARG A  71;VAL A  78","None","0.82A","3qxtB-6d11A:20.5","3qxtB-6d11A:53.47"],["3QXT_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",7,"LEU A   4;SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 107","None","1.17A","3qxtB-6dbeA:20.8","3qxtB-6dbeA:undetectable"],["3QXT_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",7,"VAL A   2;LEU A   4;ALA A  24;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.66A","3qxtB-6dbeA:20.8","3qxtB-6dbeA:undetectable"],["3QXT_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",7,"VAL A   2;LEU A   4;SER A  30;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.93A","3qxtB-6dbeA:20.8","3qxtB-6dbeA:undetectable"],["3QXT_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",6,"LEU C   4;ALA C  24;MET C  34;ARG C  72;VAL C  79;ALA C  98","None","0.59A","3qxtB-6ehgC:22.5","3qxtB-6ehgC:74.07"],["3QXT_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",6,"LEU C   4;MET C  34;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.61A","3qxtB-6ehgC:22.5","3qxtB-6ehgC:74.07"],["3QXT_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",6,"VAL C   2;LEU C   4;ALA C  24;MET C  34;ARG C  72;VAL C  79","None","0.81A","3qxtB-6ehgC:22.5","3qxtB-6ehgC:74.07"],["3QXT_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",6,"VAL C   2;LEU C   4;MET C  34;ARG C  72;VAL C  79;TYR C 112","None","0.86A","3qxtB-6ehgC:22.5","3qxtB-6ehgC:74.07"],["3QXT_B_MTXB2000_1","6gzp","Lama glama","NANOBODY","no annotation",7,"VAL A   2;LEU A   4;ALA A  24;MET A  34;ARG A  71;ALA A  94;TYR A 102","None","0.68A","3qxtB-6gzpA:22.0","3qxtB-6gzpA:undetectable"]]